SynthesisJournal of medical economics2026
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
Toby A Eyre et al.PubMed ↗Publisher ↗
No numbers read from the abstract.